893 related articles for article (PubMed ID: 17216477)
1. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
2. Potential of alfacalcidol for reducing increased risk of falls and fractures.
Ringe JD; Schacht E
Rheumatol Int; 2009 Aug; 29(10):1177-85. PubMed ID: 19159932
[TBL] [Abstract][Full Text] [Related]
3. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
Ringe JD; Faber H; Fahramand P; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
[TBL] [Abstract][Full Text] [Related]
4. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.
Ringe JD; Dorst A; Faber H; Schacht E; Rahlfs VW
Rheumatol Int; 2004 Mar; 24(2):63-70. PubMed ID: 14513268
[TBL] [Abstract][Full Text] [Related]
5. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.
Nuti R; Bianchi G; Brandi ML; Caudarella R; D'Erasmo E; Fiore C; Isaia GC; Luisetto G; Muratore M; Oriente P; Ortolani S
Rheumatol Int; 2006 Mar; 26(5):445-53. PubMed ID: 16283320
[TBL] [Abstract][Full Text] [Related]
6. Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.
Ringe JD; Schacht E
Rheumatol Int; 2007 Dec; 28(2):103-11. PubMed ID: 17668216
[TBL] [Abstract][Full Text] [Related]
7. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
8. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass.
Felsenberg D; Bock O; Börst H; Armbrecht G; Beller G; Degner C; Stephan-Oelkers M; Schacht E; Mazor Z; Hashimoto J; Roth HJ; Martus P; Runge M
J Musculoskelet Neuronal Interact; 2011 Mar; 11(1):34-45. PubMed ID: 21364273
[TBL] [Abstract][Full Text] [Related]
9. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
Rhee Y; Kang M; Min Y; Byun D; Chung Y; Ahn C; Baek K; Mok J; Kim D; Kim D; Kim H; Kim Y; Myoung S; Kim D; Lim SK
Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
[TBL] [Abstract][Full Text] [Related]
10. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.
Orimo H; Nakamura T; Fukunaga M; Ohta H; Hosoi T; Uemura Y; Kuroda T; Miyakawa N; Ohashi Y; Shiraki M;
Curr Med Res Opin; 2011 Jun; 27(6):1273-84. PubMed ID: 21554143
[TBL] [Abstract][Full Text] [Related]
11. Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
Takata S; Abbaspour A; Yonezu H; Yasui N
J Med Invest; 2007 Feb; 54(1-2):35-40. PubMed ID: 17380012
[TBL] [Abstract][Full Text] [Related]
12. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
Kushida K; Shiraki M; Nakamura T; Kishimoto H; Morii H; Yamamoto K; Kaneda K; Fukunaga M; Inoue T; Nakashima M; Orimo H
J Bone Miner Metab; 2004; 22(5):462-8. PubMed ID: 15316867
[TBL] [Abstract][Full Text] [Related]
13. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.
Ringe JD; Farahmand P; Schacht E
Rheumatol Int; 2013 Mar; 33(3):637-43. PubMed ID: 22527138
[TBL] [Abstract][Full Text] [Related]
14. [Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
Von Schacht E; Dambacher MA; Ringe JD; Dukas L
MMW Fortschr Med; 2012 Apr; 154 Suppl 1():10-21. PubMed ID: 23427364
[TBL] [Abstract][Full Text] [Related]
15. Potency of a combined alfacalcidol-alendronate therapy to reduce the risk of falls and fractures in elderly patients with glucocorticoid-induced osteoporosis.
Ringe JD; Schacht E; Dukas L; Mazor Z
Arzneimittelforschung; 2011; 61(2):104-11. PubMed ID: 21428245
[TBL] [Abstract][Full Text] [Related]
16. Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study.
Schacht E; Ringe JD
Arzneimittelforschung; 2011; 61(1):40-54. PubMed ID: 21355445
[TBL] [Abstract][Full Text] [Related]
17. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
Zhang ZL; Liao EY; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; De Peng Y; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L; Santora AC
Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192
[TBL] [Abstract][Full Text] [Related]
18. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
Guan YT; Cai LL; Ding HX; Chen GD; Hu Y
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):571-4. PubMed ID: 21029610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
